55 related articles for article (PubMed ID: 15081253)
1. An interferon-gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies.
Sutton IJ; Steele J; Savage CO; Winer JB; Young LS
J Neuroimmunol; 2004 May; 150(1-2):98-106. PubMed ID: 15081253
[TBL] [Abstract][Full Text] [Related]
2. Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.
Raspotnig M; Haugen M; Thorsteinsdottir M; Stefansson I; Salvesen HB; Storstein A; Vedeler CA
Cancer Immunol Immunother; 2017 Nov; 66(11):1463-1471. PubMed ID: 28710511
[TBL] [Abstract][Full Text] [Related]
3. Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.
Herdlevaer I; Kråkenes T; Schubert M; Vedeler CA
Ann Clin Transl Neurol; 2020 Nov; 7(11):2231-2242. PubMed ID: 33009713
[TBL] [Abstract][Full Text] [Related]
4. Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies.
Winklehner M; Bauer J; Endmayr V; Schwaiger C; Ricken G; Motomura M; Yoshimura S; Shintaku H; Ishikawa K; Tsuura Y; Iizuka T; Yokota T; Irioka T; Höftberger R
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 36070310
[TBL] [Abstract][Full Text] [Related]
5. Ovarian mass Presenting as Paraneoplastic cerebellar degeneration with peripheral neuropathy and anti-Yo antibody.
Sahoo D; Dey A; Dash A; Dash A
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38272525
[TBL] [Abstract][Full Text] [Related]
6. CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity.
Vorasoot N; Scharf M; Miske R; Thakolwiboon S; Dubey D; Mills JR; Pittock SJ; Zekeridou A; Ott A; McKeon A
Front Immunol; 2023; 14():1265797. PubMed ID: 37841252
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer revealed by a paraneoplastic cerebellar syndrome: about one case and literature review.
Adama D; Moussa B; Emmanuel M; Dennis U
Pan Afr Med J; 2015; 22():25. PubMed ID: 26664526
[TBL] [Abstract][Full Text] [Related]
8. Unusual magnetic resonance imaging and cerebrospinal fluid findings in paraneoplastic cerebellar degeneration: a sequential study.
de Andrés C; Esquivel A; de Villoria JG; Graus F; Sánchez-Ramón S
J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):562-3. PubMed ID: 16543544
[No Abstract] [Full Text] [Related]
9. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues.
Corradi JP; Yang C; Darnell JC; Dalmau J; Darnell RB
J Neurosci; 1997 Feb; 17(4):1406-15. PubMed ID: 9006982
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific killer cells in paraneoplastic cerebellar degeneration.
Albert ML; Darnell JC; Bender A; Francisco LM; Bhardwaj N; Darnell RB
Nat Med; 1998 Nov; 4(11):1321-4. PubMed ID: 9809559
[TBL] [Abstract][Full Text] [Related]
11. CD8 positive T-cell infiltration in the dentate nucleus of paraneoplastic cerebellar degeneration.
Aye MM; Kasai T; Tashiro Y; Xing HQ; Shirahama H; Mitsuda M; Suetsugu T; Tanaka K; Osame M; Izumo S
J Neuroimmunol; 2009 Mar; 208(1-2):136-40. PubMed ID: 19217169
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration.
Carpenter EL; Vance BA; Klein RS; Voloschin A; Dalmau J; Vonderheide RH
J Neuroimmunol; 2008 Jan; 193(1-2):173-82. PubMed ID: 18053582
[TBL] [Abstract][Full Text] [Related]
13. A Breakdown of Immune Tolerance in the Cerebellum.
Hampe CS; Mitoma H
Brain Sci; 2022 Feb; 12(3):. PubMed ID: 35326284
[TBL] [Abstract][Full Text] [Related]
14. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.
Panja D; Vedeler CA; Schubert M
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):141-156. PubMed ID: 29679372
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review.
Venkatraman A; Opal P
Ann Clin Transl Neurol; 2016 Aug; 3(8):655-63. PubMed ID: 27606347
[TBL] [Abstract][Full Text] [Related]
16. 'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook.
Jarius S; Wildemann B
J Neuroinflammation; 2015 Sep; 12():168. PubMed ID: 26377319
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.
Schubert M; Panja D; Haugen M; Bramham CR; Vedeler CA
Acta Neuropathol; 2014 Dec; 128(6):835-52. PubMed ID: 25341622
[TBL] [Abstract][Full Text] [Related]
18. Neuronal autoantigens--pathogenesis, associated disorders and antibody testing.
Lancaster E; Dalmau J
Nat Rev Neurol; 2012 Jun; 8(7):380-90. PubMed ID: 22710628
[TBL] [Abstract][Full Text] [Related]
19. Paraneoplastic syndromes of the CNS.
Dalmau J; Rosenfeld MR
Lancet Neurol; 2008 Apr; 7(4):327-40. PubMed ID: 18339348
[TBL] [Abstract][Full Text] [Related]
20. Paraneoplastic neurological syndromes.
Honnorat J; Antoine JC
Orphanet J Rare Dis; 2007 May; 2():22. PubMed ID: 17480225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
